Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Lindus Health | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
A 6-month randomised controlled trial to evaluate the impact of text message support on symptom control and inhaler adherence for patients with asthma and/or COPD
This trial will be a 6-month prospective, randomised controlled trial in which the study population is randomly allocated (1:1) to an intervention or control group. The trial is multicentre and is non-blind. All patients in both groups will continue to receive their usual care for the duration of the study. Randomisation will be at the individual level. Participants will be randomly allocated as per a computer-generated randomisation list using a random number generator as part of the Microsoft .NET framework.
This is a behavioural intervention. The intervention will consist of a series of supportive text messages to patients from their GP practice over a 6 month period. The messages will vary in frequency from 2 or 3 in the first weeks of the trial to only 1 or 2 a month in the final months of the trial. The content of the messages will vary; some will contain information about how to use a preventer inhaler, some will emphasise the importance of using it, and some will provide simple reminders to patients to take their inhaler.
All participants will continue to receive their usual care throughout the duration of the study; the text message intervention with be in addition to their usual care.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Supportive Text Messagses | Experimental | The intervention group will receive a series of supportive text messages over the 6 month trial period, varying in content and frequency. They will also be asked to provide self reported data on their symptoms and their adherence at 3 points in time (start, mid-point, and end of trial). |
|
| Control Group | No Intervention | The control group will receive no supportive text messages over the period of the trial. They will be asked to only provide self reported data on their symptoms and their adherence at 3 points in time (start, mid-point, and end of trial). |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Supportive text messages | Behavioral | The intervention group will receive a series of supportive text messages over the 6 month trial period, varying in content and frequency. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Improved self-reported medication taking as measured by the The Medication Adherence Report Scale (MARS-5) Questionnaire | Changes in the MARS-5 Questionnaire | Baseline to 13 and 26 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Improved control of asthma symptoms as measured by the Asthma Control Test | Changes in the Asthma Control Test | Baseline to 13 and 26 weeks (for asthma patients) |
| A reduction in the interval between patients requesting preventer inhaler prescriptions |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Luke Twelves | Lindus Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Medical Centre | Canterbury | Kent | CT2 7PB | United Kingdom | ||
| Gravesend Medical Centre |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Reduction in days between consecutive preventer inhaler prescription requests
| Baseline to 13 and 26 weeks |
| Difference in emergency admissions | Differences in the number of emergency admissions between the intervention and control group | Over 26 weeks |
| Differences in NHS utilisation | Differences in the utilisation of NHS resources between the intervention and control group | Over 26 weeks |
| Gravesend |
| Kent |
| DA12 2EN |
| United Kingdom |
| Jubilee Medical Centre | Longfield | Kent | DA3 7QD | United Kingdom |
| Marlowe Park Medical Centre | Rochester | Kent | ME2 2PW | United Kingdom |
| High Oak Surgery | Dudley | West Midlands | United Kingdom |
| Lion Health | Stourbridge | West Midlands | DY8 3SS | United Kingdom |
| Wordsley Green Health Centre | Worsley | West Midlands | DY8 5PD | United Kingdom |
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |